Revelation Biosciences, Inc. (REVBW) cash flow statement

REVBWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVB

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 6/30

$0.01+0.00 (0.00%)

Close on Oct 30, 2026Market cap $16.05MP/E –Yield –

Revelation Biosciences, Inc. cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31
Stock-Based Compensation	1.24	0.84	0.60	0.30	0.33	0.36	0.17	0.13	0.13	0.16	0.16	0.16	0.16	0.20	0.30	0.37	0.47	0.51	0.47	–	–	–	–
Change in Accounts Payable	0.10	0.17	-0.21	-2.11	-0.45	-1.06	-0.58	1.80	0.29	0.90	0.75	0.79	0.00	-0.76	-0.67	-1.17	-0.60	-0.23	-0.27	–	–	–	–
Operating Cash Flow	-9.33	-8.69	-8.27	-10	-18	-18	-18	-17	-9.04	-8.55	-7.29	-6.23	-6.25	-7.96	-11	-13	-14	-14	-11	-8.42	-6.19	-2.61	-0.22
Capital Expenditures	–	–	–	–	–	–	-0.02	–	–	–	–	–	–	–	–	–	–	–	-0.13	–	–	–	–
Sale & Maturity of Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.53	–	–	–	–
Investing Cash Flow	–	–	–	–	–	–	-0.02	–	–	–	–	–	–	–	–	–	–	–	-0.13	–	–	–	–
Stock Issued	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.60	–	–	–	–
Financing Cash Flow	16	–	12	–	–	–	13	9.16	5.42	5.42	14	14	18	18	15	15	11	11	8.00	79	82	82	74
Net Change in Cash	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-3.32	–	–	0.01
Free Cash Flow	–	–	–	–	–	–	-18	–	–	–	–	–	–	–	–	–	–	–	-11	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -131.4%

Financial strength

Current ratio: 6.21
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 610.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.59
Dividend yield: –